Why investors are taking another look at kidney disease

0:00-18:26

In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsBruce Culleton, CEO, ProKidneyDemetri Maxim, CEO, NephrogenDisclaimer: The views expressed in this discussion by guests are their own and do not re...

Publisher

BioSpace

Published

October 22, 2026

Duration

18 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#investors #taking #kidneydisease #lifesciences

The Nile